MARKET

NTRA

NTRA

Natera Inc
NASDAQ
44.98
-1.08
-2.33%
Opening 13:09 09/29 EDT
OPEN
45.44
PREV CLOSE
46.05
HIGH
45.72
LOW
43.32
VOLUME
380.94K
TURNOVER
13.06M
52 WEEK HIGH
121.05
52 WEEK LOW
26.10
MARKET CAP
4.36B
P/E (TTM)
-7.4100
1D
5D
1M
3M
1Y
5Y
Natera Announces 2025 ESG Goals with Publication of 2021 Report
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of its 2021 Environmental, Social and Governance (ESG) report detailing the company's commitment to environmental sustainability, social equity a...
PR Newswire · 4h ago
BRIEF-Natera Presents New Colorectal And Breast Cancer Data At Esmo 2022
BRIEF-Natera Presents New Colorectal And Breast Cancer Data At Esmo 2022
Reuters · 09/12 13:33
Natera Presents New Colorectal And Breast Cancer Data From The CIRCULATE-Japan Study At ESMO
Data from the largest real-world MRD study to date in resectable colorectal cancer reinforces the findings from the recent CIRCULATE-Japan study AUSTIN, Texas, Sept. 12, 2022 /PRNewswire/ -- Natera,
Benzinga · 09/12 13:29
Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the 2022 European Society for Medical Oncology (ESMO) World Congres...
PR Newswire · 09/12 13:27
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades
Benzinga · 08/25 14:34
Exact Sciences, Guardant rise as Credit Suisse initiate coverage with bullish views
Diagnostic test makers Exact Sciences (NASDAQ:EXAS), Guardan...
Seekingalpha · 08/25 13:52
Natera Earns Great Place to Work Certification™ for Second Consecutive Year
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, is proud to be certified by Great Place to Work® for the second consecutive year. The certification is based entirely on how current employees rate their experience working at Natera in...
PR Newswire · 08/25 12:35
Credit Suisse Initiates Coverage On Natera with Outperform Rating, Announces Price Target of $70
Credit Suisse analyst Dan Leonard initiates coverage on Natera (NASDAQ:NTRA) with a Outperform rating and announces Price Target of $70.
Benzinga · 08/25 09:27
More
About NTRA
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening (HCS), Spectrum Pre-implantation Genetics (Spectrum), Anora Miscarriage Test (Anora), Non-Invasive Paternity Testing (PAT) and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology.

Webull offers kinds of Natera Inc stock information, including NASDAQ:NTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NTRA stock methods without spending real money on the virtual paper trading platform.